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Abstract
Background: The national incidence of and risk factors for hospitalized poisonings in renal
transplant recipients has not been reported.
Methods: Historical cohort study of 39,628 renal transplant recipients in the United States Renal
Data System between 1 July 1994 and 30 June 1998. Associations with time to hospitalizations for
a primary diagnosis of poisonings (ICD-9 codes 960.x-989.x) within three years after renal
transplant were assessed by Cox Regression.
Results: The incidence of hospitalized poisonings was 2.3 patients per 1000 person years. The
most frequent causes of poisonings were immunosuppressive agents (25.3%), analgesics/
antipyretics (14.1%), psychotropic agents (10.0%), and insulin/antidiabetic agents (7.1%). In Cox
Regression analysis, low body mass index (BMI, <21.6 vs. >28.3 kg/m2, adjusted hazard ratio (AHR),
3.02, 95% CI, 1.45–6.28, and allograft rejection, AHR 1.83, 95% CI, 1.15–2.89, were the only factors
independently associated with hospitalized poisonings. Hospitalized poisonings were independently
associated with increased mortality (AHR, 1.54, 95% CI 1.22–1.92, p = 0.002).
Conclusions:  Hospitalized poisonings were associated with increased mortality after renal
transplantation. However, almost all reported poisonings in renal transplant recipients were due
to the use of prescribed medications. Allograft rejection and low BMI were the only independent
risk factors for poisonings identified in this population.
Background
Poisonings are among the most frequent indications for
hospitalization in the United States [1]. However, the fre-
quency of hospitalizations for poisonings (drug overdose
or toxicity) in renal transplant recipients has been infre-
quently reported, [2,3] in contrast to its occurrence in kid-
ney donors [4,5]. Because many medications used by
transplant recipients can be toxic, it might be expected
that renal transplant recipients would have a higher risk of
poisonings than the general population, especially in the
first post-transplant year when dosages of immunosup-
pressive medications are usually at their highest. Analysis
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of the incidence and causes of poisonings represents an
opportunity to explore the frequency and risk factors for
medical errors, since many such complications may be
avoidable. The impact of hospitalized poisonings on sub-
sequent survival after renal transplantation has also not
been assessed. Therefore, we analyzed national diata from
the USRDS report. Our objectives were to determine the
risk factors for and mortality associated with hospitalized
poisonings after renal transplantation.
Methods
Patient population
This study used data from the United States Renal Data
System (USRDS), using standard analysis files (SAF's) as
of May 2000. The variables included in the USRDS stand-
ard analysis files (SAF's), as well as data collection meth-
ods and validation studies, are listed at the USRDS
website, under 'Researcher's Guide to the USRDS Data-
base', Section E, 'Contents of all the SAF's',  [http://
www.usrds.org] and published in the USRDS. The demo-
graphics of the renal transplant population have been pre-
viously described (2001 USRDS report). SAF.TXUNOS
was used as the primary dataset, and merged with varia-
bles from SAF.HOSP for hospitalization data, and SAF.PA-
TIENTS for dates and causes of death as well as causes of
renal disease, as previously reported [6–8]. Patient charac-
teristics and treatment factors were those at the date of
transplant. Recipients of organs other than kidneys were
excluded.
Outcome definition
We conducted an historical cohort study of the incidence,
risk factors and associated patient survival for hospitalized
cases of poisonings (based on International Classification
of Diseases-9th Modification Diagnosis Codes (ICD9)
960.x-989.x) as a primary discharge diagnosis in renal
transplant recipients. Only the primary discharge diagno-
sis was used to ensure these were active diagnoses, ie, to
exclude diagnoses with "history of poisonings." These di-
agnoses include potential overdoses for heroin, but not
for cocaine or other illicit drugs. These diagnoses also in-
clude most known causes of environmental exposures, in-
cluding minerals, pesticides, vaccinations, miscellaneous
chemicals and certain foodstuffs. The first hospitalization
for poisonings after the first renal transplant for a given in-
dividual occurring on or after 1 July 1994 and before 1
July 1998 (which could include a repeat transplant), with
followup time truncated at three years was counted in
analysis. Hospitalizations were chosen because they were
more accessible in the database and less subject to inter-
pretation than outpatient cases of poisonings, especially
since the USRDS database has no information on con-
firmatory studies. Hospitalization data for transplant re-
cipients may be unreliable after the patient has survived ≥
3 years post transplant, when hospitalization reporting to
Medicare for patients 65 years or younger is no longer re-
quired. However, Medicare reporting starts immediately
after transplant, regardless of preceding dialysis status. All
hospitalizations with a primary discharge diagnosis for
poisonings were extracted from SAF.HOSP, merged with
the transplant file, and hospitalizations outside the range
of the study period were excluded. Hospitalizations for
poisonings occurring at any time after renal transplant, in-
cluding after graft failure (censored for patient death),
were counted in analysis.
Variables used in analysis
The independent associations between patient factors and
hospitalizations for poisonings were examined using mul-
tivariate analysis with stepwise Cox Regression (likeli-
hood ratio method) including recipient and donor age,
recipient race, gender, weight, pretransplant dialysis (yes/
no), year of transplant, duration of dialysis prior to trans-
plantation, total follow-up time, repeat transplant, donor
cytomegalovirus serology, dialysis in the first week after
transplant (delayed graft function, yes/no), rejection (di-
agnosis or treatment) occurring during the first six
months after transplant, induction antibody therapy,
maintenance immunosuppressive medications at time of
discharge after transplant surgery, graft loss (analyzed as a
time-dependent covariate as previously described), [9]
and cause of ESRD (diabetes, systemic lupus erythemato-
sus (because of the potential effect of corticosteroid ther-
apy prior to renal transplantation), hypertension and
glomerulonephritis). Episodes of rejection were not re-
stricted to those occurring in the first year, in contrast to
studies of allograft function, since there is no evidence
that late (vs. early) rejection has a different impact on poi-
sonings. The total cumulative dose of prednisone was not
available in the USRDS. Both the USRDS and UNOS track
the numbers of days of prednisone administered prior to
initial hospital discharge, however values were missing for
>90% of patients in both databases and could not be used
as a covariate in the above analyses. Maintenance immu-
nosuppressive medication use at the time of discharge af-
ter transplantation was also analyzed as a preexisting
covariate. Information on use of medications (other than
immunosuppressive medications), alcohol, tobacco, or
radiologic procedures was not available.
Survival times
We defined patient survival times as the time from when
patients had their first renal transplant during the study
period to the time of death or most recent follow-up date
(which was considered May 2000). For time to poison-
ings, survival time was defined as the time from first renal
transplant until hospitalization for poisonings, with pa-
tients censored at death, loss to followup, or end of the
study (which was considered 31 December 1999, since
this was the most recent hospitalization date). The patientBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/10
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survival probabilities were estimated by using the Kaplan
Meier method.
Statistical analysis
All analyses were performed using SPSS 9.0 TM (SPSS,
Inc., Chicago, IL). Files were merged and converted to
SPSS files using DBMS/Copy (Conceptual Software, Hou-
ston, TX). Univariate analysis was performed with Chi-
square testing for categorical variables and Student's two-
sided t-test for continuous variables. Variables with p <
0.05 in univariate analysis for a relationship with develop-
ment of hospitalization for poisonings were entered into
multivariate analysis as covariates. Kaplan-Meier analysis
was used to construct survival plots of time to hospital-
ized poisonings after renal transplantation. Log-log plots
were inspected to assess for proportionality of hazards
over time. Stepwise Cox proportional hazards regression
(likelihood ratio method) was used to model the associa-
tion of patient factors with hospitalized poisonings. In or-
der to control for misspecification errors, a random
sample of 25% of patients was excluded from analysis and
coefficients estimated for this sample. The sample was fro-
zen, and coefficients estimated from the 25% sample. Be-
cause hospitalizations for poisonings were uncommon,
Poisson Regression was used for validation, using the
GENLOG approximation in SPSS. In order to estimate the
association of hospitalizations with all-cause mortality,
Cox-nonproportional hazards Regression was utilized.
Times after hospitalization for poisonings were entered as
1, all other times were entered as 0, as previously de-
scribed [10,11]. Patients with missing information for var-
iables were excluded from the multivariate models,
resulting in models smaller than the total population. Hi-
erarchically well-formed models were used for the assess-
ment of interaction terms [11].
Results
There were 42,096 solitary renal transplant recipients in
the United States Renal Data System transplanted from 1
July 1994 to 30 June 1998, of whom 39,628 had complete
enough information to calculate survival times. Mean fol-
lowup was 1.89 ± 1.15 years (median, 1.91 years). Of the
study population, 170 recipients were hospitalized with a
primary discharge diagnosis of poisonings during the
study period, with 188 total hospitalizations. The cumu-
lative incidence of hospitalizations for poisonings during
the study period was 2.3/1000 person years. Primary diag-
noses for hospitalized poisonings are shown in Table 1.
Suicide was not listed as an eventual primary cause of
death among patients hospitalized for poisonings, nor
was attempted suicide (E956, "Suicide and self-inflicted
injuries by cutting and piercing instrument," or E958.9
"unspecified cause of suicide") listed as a secondary or ter-
tiary discharge diagnosis among these patients. The mean
length of stay for patients hospitalized for poisonings was
4.05 ± 4.15 days (range, 1–41 days). Among renal trans-
plant recipients with diabetes, the most common cause of
hospitalized poisonings was insulin/antidiabetic agents,
while in patients who experienced allograft rejection, the
most common cause of hospitalized poisonings was im-
munosuppressive agents.
The time to hospitalization for poisonings is shown in
Figure 1. As shown, the risk of hospitalized poisonings
were highest in the first few months after renal transplan-
tation, with a consistent risk afterward. Figures 2 and 3
show the time to hospitalization for poisoning stratified
by allograft rejection and body mass index, respectively.
In Figure 2, analysis was limited to patients who survived
at least 6 months after transplant. In figure 3, the risk of
poisonings for all transplant recipients was similar for the
first six months by both survival plots and log-log plots.
Therefore, since this violated the proportional hazards as-
sumption, multivariate analysis was also performed limit-
ed to patients who survived at least six months after
transplant.
Characteristics of the study population, including results
of both univariate and multivariate analysis, are shown in
table 2 (see additional file 1). In univariate analysis, fac-
tors associated with an increased risk of hospitalized poi-
sonings were low body mass index, graft loss, cadaveric
donor, rejection within 6 months after transplant, and di-
abetes, while male gender was associated with reduced
risk of poisoning. In Cox Regression analysis, however,
the only two factors independently associated with hospi-
talized poisoning were low body mass index and allograft
rejection. There were no significant interactions between
covariates, specifically no interactions between mainte-
nance or induction medications, or between age and body
mass index. In analysis limited to recipients age 18 and
over, low body mass index (as assessed in Table 23, AHR,
2.74, 95% CI, 1.29–5.82, p = 0.009) and rejection (AHR,
1.88, 95% CI 1.16–3.05, p = 0.01) were again the only fac-
tors significantly associated with hospitalized poisonings.
Mortality after hospitalizations for poisoning, which was
constant over time, is shown in Figure 4. Hospitalizations
for poisonings were independently associated with in-
creased mortality in Cox Regression (AHR, 1.54, 95% CI
1.22–1.92, p = 0.002).
Discussion
The present study demonstrated that almost all hospitali-
zations for poisonings after renal transplantation were
due to the use of prescription medications, even though
ICD9 codes 960–989.x also include poisonings from en-
vironmental toxins, vaccines, and anesthetic agents. Be-
cause many immunosuppressive medications are toxic,
this was not a surprising finding. However, reports fromBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/10
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Figure 1
Time to hospitalizations for poisonings after renal transplantation in the United States, 1 July 1994–30 June 1998, N = 39,628.
The risk of hospitalized poisonings was highest in the first 1–2 months after renal transplantation, followed by a consistent risk
afterward.
Table 1: Most Frequent Diagnoses for Hospitalized poisonings after Renal Transplantation
Diagnosis ICD9 Code N (%)
Anti-neoplastic/immunosuppression 963.1 53 (25.3)
Analgesics/Antipyretics 965.x 24 (14.1)
Opiates 965.90 14 (8.2)
Aromatic AnalgesicsA 965.4 6 (3.5)
Analgesics/Antipyretics 965.8 4 (2.4)
Salicylates 965.1 1 (0.6)
Psychotropic Agents 969.x 17 (10.0)
Benzodiazepine/Tranquilizer 969.4 10 (5.9)
Antidepressant 969.0 6 (3.5)
Psychostimulants 969.7 1 (0.6)
Insulin/Antidiabetic 962.3 12 (7.1)
Antihypertensives 972.6 4 (2.4)
Miscellaneous 977.8 15 (8.8)
Hydantoin 966.1 5 (2.9)
Corticosteroids 962.0 2 (1.2)
Antiallergic/antiemetic 963.0 2 (1.2)
A Not elsewhere classified, including Acetanilid, Paracetamol [acetaminophen] and Phenacetin [acetophenetidin]
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the medical literature have been infrequent, as indicated
previously. In fact, a Medline search for the terms "medi-
cation error transplant" yielded only 14 papers, [12,13]
and none was returned for the search "medication error
renal transplant." Therefore, review of the medical litera-
ture might give a misleading indication of the frequency
of this complication. Although reported hospitalizations
for poisonings as a primary diagnosis were not common,
hospitalizations for poisonings were independently asso-
ciated with increased mortality in renal transplant recipi-
ents, and also represented potentially avoidable
morbidity with a mean length of stay of over 4 days.
Anti-neoplastic/immunosuppressive agents were the most
common cause of poisonings in this population, as would
be expected. The current study almost certainly underesti-
mates the incidence of serious immunosuppressive drug
toxicity in this population. In addition, renal transplant
recipients have many potential indications for the use of
analgesics/antipyretics, post-operative pain among them
[14]. The frequent occurrence of poisonings due to anal-
gesics after renal transplantation may therefore seem un-
derstandable. However, although the risk of poisonings
was highest in the first few months after transplantation,
the increase in relative risk in this time was not visually re-
markable (Figure 1), and the risk of poisoning continued
in a constant fashion after transplant. There was certainly
no early peak followed by a dramatic stabilization in rates
of poisonings, as has been demonstrated for hospitaliza-
tions for cytomegalovirus disease, [15] contrary to what
might have been expected. This suggests the possibility
that either the dosing or use of these medications may not
be adjusted optimally after renal transplantation.
Benzodiazepines/tranquilizers were the third most com-
mon cause of poisonings in this study. It is noteworthy
that calcineurin inhibitor toxicity may mimic anxiety or
nervousness, [16] which are common indications for the
use of benzodiazepines. In addition, many antidepressive
agents may raise levels of calcineurin inhibitors [17]. Re-
sults of the present study raise the possibility that indica-
tions for treatment with benzodiazepines may actually
represent toxicities of calcineurin antagonists, which
might be best managed by adjusting the dose of the cal-
cineurin inhibitors. Until then, we would suggest that the
possibility of other drug toxicities, including drug interac-
tions, be thoroughly excluded before prescribing benzodi-
azepines in this population. Often overlooked is the effect
of erratic compliance with azole antifungals, anticonvul-
sants or other medications that inhibit or induce cal-
cineurin inhibitors.
The high frequency of poisonings due to insulin/antidia-
betic agents is also not surprising given the high frequency
Figure 2
Time to Hospitalization for Poisonings after Renal Transplantation, stratified by allograft rejection occurring within 6 months
after transplant. Patients with a history of allograft rejection (REJ) had a significantly higher risk of hospitalized poisoning than
those who did not (p = 0.01 by Log Rank Test).
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of diabetes among renal transplant recipients, although
diabetes was not an independent risk factor for poison-
ings in the present analysis. This suggests that diabetic
transplant recipients should be monitored with particu-
larly close attention, perhaps in concert with regular visits
with a pharmacist [18] or as part of a disease management
program to reduce medical errors [19].
Considering that almost all causes of hospitalized poison-
ings after renal transplantation were attributed to pre-
scription medications, the risk factors for hospitalized
poisonings in the present study, namely allograft rejection
and low body mass index, are all the more remarkable.
The significance of a low body mass index as an independ-
ent risk factor for poisonings in this analysis as a risk fac-
tor for hospitalized poisonings, independent of age,
suggests the possibility of suboptimal dose adjustment of
medications. This particularly applies to calcineurin in-
hibitors, which are lipid soluble and have a large volume
of distribution. Most calcineurin inhibitors are initiated
adjusted for patient weight. However, in a small percent-
age of patients currently recommended doses may still re-
sult in toxicity. Area-under-the-curve monitoring gives an
estimate of total drug exposure and may help minimize
toxicity, particularly in patients with unusual clinical re-
sponses to standard dosing [20]. It would be useful to test
this hypothesis in future studies.
The association of poisonings with allograft rejection in
this category of patients may represent toxicity due to bo-
lus intravenous or high dose oral corticosteroid therapy,
or significant drug-drug interactions in this setting, which
the database could not determine. However, the findings
Figure 3
Time to Hospitalization for Poisonings after Renal Transplantation, stratified by quartiles of BMI (1 =< 21.6 kg/m2, 2 = 21.6–
24.9 kg/m2, 3 = 25.0–28.3 kg/m2, 4 => 28.3 kg/m2). Recipients with BMI < 21.6 kg/m2 had a significantly higher risk of hospital-
ized poisonings compared to recipients with BMI > 28.3 kg/m2, p = 0.01 by Log Rank Test.
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Table 3: Cox Regression Analysis of Factors Associated with Hos-
pitalized Poisonings
NH R A (95% CI) P value
BMI <21.6 vs. >28.3 kg/m2 3.02 (1.45–6.28) 
B
0.003
Rejection within 6 months after 
transplant
1.83 (1.15–2.89) 
B
0.011
N in Final Model 21,575
AAdjusted hazard ratio by Cox Regression analysis of time to hospi-
talization for poisonings, 95%CI = 95% confidence interval Analysis 
using these variables was limited to patients who survived at least 6 
months after transplant CAnalyzed as a time-dependent covarariate, 
all times after graft loss = 1, all times before graft loss = 0BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/10
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of the present analysis suggest a need for providers nation-
ally to reevaluate the use of immunosuppressive agents in
a systematic fashion after transplantation. The manage-
ment of renal transplant patients is certainly not uniform;
in some centers, the primary transplant surgeon may con-
tinue management of the patient up to a year or more after
transplant, while in other centers a nephrologist or even
primary care physician may assume primary management
of the patient after the first transplant month. It is possible
that more standardized guidance on dosing and the pos-
sibility of drug interactions would be beneficial. Current-
ly, there are no clinical practice guidelines on the dosing
of transplant related medications, although certain insti-
tutional guidelines do exist [21].
The present study is limited by use of primary hospitaliza-
tion diagnoses for outcomes. The true frequency of poi-
sonings and medication errors in the renal transplant
population is most likely underestimated. Because of the
study's retrospective nature, many other factors could not
be validated. Patients with multiple potential causes for
admission may not have been included among patients
with hospitalized poisonings. However, the study is pop-
ulation based, and because accurate coding for hospitali-
zation discharge is required, is likely to be less subject to
reporting bias than case reports of poisonings in the med-
ical literature.
The present study could not determine the reason for poi-
sonings. In short, the possibilities of patient error vs. pro-
vider error could not be distinguished. However,
consultation with pharmacists may reduce both [22]. Giv-
en the looming shortage of nephrologists, [23] nurses,
and other medical providers, [24] multiple safeguards
need to be established to minimize the possibility of error
as much as possible in these complex and challenging pa-
tients. This is particularly true given the significant associ-
ations of both body mass index and allograft rejection
with hospitalized poisonings in this analysis, which may
indicate that more complex and individualized methods
of medication dosing may be necessary after renal trans-
plantation than are currently used. The present study
identifies specific targets for investigation and improve-
ment.
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Figure 4
Mortality after Hospitalization for Poisonings. The risk of mortality after poisonings was constant over time. Hospitalizations
for poisonings were independently associated with increased mortality in Cox Regression (AHR, 1.54, 95% CI 1.22–1.92, p =
0.002).
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